Company news

Organon & Co. (NYSE:OGN) news

Organon & Co. news releases on 6ix. Latest, Oct 1, 2026: Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical…

Organon & Co. (NYSE:OGN) news

Press releases & updates

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Organon Announces Quarterly Dividend

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada

Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19

Organon to Present New Research on Access and Value at ISPOR 2026

Organon Reports Results for the First Quarter Ended March 31, 2026

Organon Cancels First Quarter Earnings Call

European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe

Sun Pharma signs Definitive Agreement to Acquire Organon

Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis

Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants

Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Organon Completes Divestiture of JADA® System to Laborie

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON(R) (etonogestrel implant) 68 mg Radiopaque

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

TetraScience and Organon Collaborate to Modernize Quality Control Data Management

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Organon Reports Results for the Third Quarter Ended September 30, 2025

New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Laborie Announces Agreement to Acquire the JADA® System from Organon

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.